Investors
Corporate Profile
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from GSDIa, phenylketonuria (PKU), Wilson disease, and citrullinemia; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in OTC deficiency, which is in a Phase 1/2 clinical trial. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.
Presentations
DateTitle
08/18/17
Dimension Therapeutics Corporate Presentation August 2017
Download Documentation
Stock
DMTX (Common Stock) $5.950.00 (0.00%)
High $6.00
Events
Dimension Therapeutics Q4 2016 Earnings and Corporate Update Conference Call
03/09/17 8:30 a.m. ET
E-mail Alerts
Sign up to receive
E-mail Alerts
 
News
October 26, 2017
Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx’s Acquisition of Dimension
NOVATO, Calif. and CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) ("Ultragenyx" or the "Company"), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Dimension Therapeutics, Inc. (NASDAQ:DMTX) ("Dimension") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Ultragenyx's proposed acquisition of Dimens[...]  Read More /
October 02, 2017
Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”
REGENXBIO Waives Matching Rights CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (“Dimension”) (NASDAQ:DMTX) announced today that the Dimension Board of Directors (the “Dimension Board”) has determined that an unsolicited proposal received from Ultragenyx Pharmaceutical Inc. (“Ultragenyx”) (NASDAQ:RARE) constitutes a “Superior Proposal” as defined in Dimension’s existing merger agreement with REGENXBIO Inc. (“REGENXBIO”) (NASDAQ:RGNX), dated as of August 24,[...]  Read More /
September 19, 2017
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
Dimension to Begin Discussions with Ultragenyx CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX), a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, announced today that its Board of Directors has determined in good faith, after consultation with its financial advisor and outside legal counsel, that the non-binding, unsolicited proposal from Ultr[...]  Read More /
Data provided by Nasdaq. Minimum 15 minutes delayed.